The unit’s upcoming string of exercises, called “Lightning Surge,” begins in January 2026, and will be conducted in tandem with the 4 ID “Ivy” Division’s Ivy Sting exercise series for NGC2 prototype ...
Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results